Filtered By:
Condition: SARS
Vaccination: Influenza Vaccine
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1002 results found since Jan 2013.
Identification of γ-Fagarine as a novel antiviral agent against respiratory virus (hMPV) infection
In this study, we aim to investigate the effect of γ-Fagarine on hMPV infection and explore its underlying molecular mechanisms. Vero-E6 and 16HBE cells were used as cell models. Virus replication and microcosm character were explored in Vero-E6 cells. Then, the antiviral activities were investigated by quantitative real-time PCR (RT-qPCR), western blotting (WB), and indirect immunofluorescence assays (IFAs) in Vero-E6 and 16HBE. Potential mechanisms of γ-Fagarine related to HSPG and lysosome pH were assessed in 16HBE cells. Lastly, a virus-infected mouse model was established and antiviral assay in vivo was conducted. ...
Source: Virus Research - September 21, 2023 Category: Virology Authors: Jinhua Li Yao Zhao Ying Dai Junning Zhao Source Type: research
Patient-reported reactogenicity and safety of COVID-19 vaccinations vs. comparator vaccinations: a comparative observational cohort study
CONCLUSION: The rate of adverse reactions after established vaccinations was roughly comparable to previous studies. Two weeks after vaccination, participants in the SARS-CoV-2 vaccination group reported more local and systemic local reactions than participants in the comparator group. In the further course, however, there were no higher odds of medical consultations in either of the two groups. Thus, altogether, we assume comparable safety.TRIAL REGISTRATION: DRKS-ID DRKS00025881 and DRKS-ID DRKS00025373.PMID:37726711 | DOI:10.1186/s12916-023-03064-6
Source: Herpes - September 19, 2023 Category: Infectious Diseases Authors: Felix Werner Nikoletta Zeschick Thomas K ühlein Philipp Steininger Klaus Überla Isabelle Kaiser Maria Sebasti ão Susann Hueber Lisette Warkentin Source Type: research
Comparative effectiveness of mRNA-1273 and BNT162b2 COVID-19 vaccines in immunocompromised individuals: a systematic review and meta-analysis using the GRADE framework
ConclusionThis GRADE meta-analysis based on a large number of consistent observational studies showed that the mRNA-1273 COVID-19 vaccine is associated with improved clinical effectiveness in IC populations compared with BNT162b2.
Source: Frontiers in Immunology - September 12, 2023 Category: Allergy & Immunology Source Type: research
TWiV 1042: Clinical update with Dr. Daniel Griffin
In his weekly clinical update, Dr. Griffin discusses China’s health authorities fighting surge in cases of Mpox unknown origin, analysis of seasonal variation of antibiotic prescribing for respiratory tract diagnoses in primary care practices, prevalence and associated outcomes of co-infection between SARS-CoV-2 and influenza, comparison of bivalent and monovalent mRNA vaccine boosters, optimal duration of systemic corticosteroids in COVID-19 treatment, acute blood biomarker profiles predict cognitive deficits 6 and 12 months after COVID-19 hospitalization, temporal changes in fecal microbiota of patients infected with C...
Source: This Week in Virology - MP3 Edition - September 9, 2023 Category: Virology Authors: Vincent Racaniello Source Type: podcasts
Optimisation of SARS-CoV-2 peptide stimulation and measurement of cytokine output by intracellular flow cytometry and bio-Plex analysis
J Immunol Methods. 2023 Sep 6:113556. doi: 10.1016/j.jim.2023.113556. Online ahead of print.ABSTRACTOur study was conducted to optimise a peptide stimulation and an intracellular cytokine staining protocol, alongside Bio-Plex supernatant analysis, for use in patients who had previously contracted SARS-CoV-2 or received vaccination against this virus in a clinical laboratory setting. Peripheral Blood Mononuclear Cell extraction and cryopreservation allowed for cells to be stored long term and enhanced logistical processing of samples. Viability and functionality of cells were analysed by flow cytometric methodology using vi...
Source: Journal of Immunological Methods - September 8, 2023 Category: Allergy & Immunology Authors: Jemma Victoria Taylor Emma Louise Callery Anthony Rowbottom Source Type: research
Age-specific severity of severe acute respiratory syndrome coronavirus 2 in February 2020 to June 2021 in the Netherlands
CONCLUSION: Whereas the increase in severity of Severe Acute Respiratory Syndrome Coronavirus 2 with age remained stable, the risk of death upon infection decreased over time. A significant drop in risk of death among elderly coincided with the introduction of COVID-19 vaccination.PMID:37621921 | PMC:PMC10444602 | DOI:10.1111/irv.13174
Source: Respiratory Care - August 25, 2023 Category: Respiratory Medicine Authors: Pieter T de Boer Jan van de Kassteele Eric R A Vos Liselotte van Asten Dave A Dongelmans Arianne B van Gageldonk-Lafeber Gerco den Hartog Agnetha Hofhuis Fiona van der Klis Dylan W de Lange Lenny Stoeldraijer RIVM COVID ‐19 epidemiology and surveillance Source Type: research
The Possible Mechanisms of Cu and Zn in the Treatment and Prevention of HIV and COVID-19 Viral Infection
Biol Trace Elem Res. 2023 Aug 23. doi: 10.1007/s12011-023-03788-9. Online ahead of print.ABSTRACTDue to their unique properties and their potential therapeutic and prophylactic applications, heavy metals have attracted the interest of many researchers, especially during the outbreak of COVID-19. Indeed, zinc (Zn) and copper (Cu) have been widely used during viral infections. Zn has been reported to prevent excessive inflammatory response and cytokine storm, improve the response of the virus to Type I interferon (IFN-1), and enhance the production of IFN-a to counteract the antagonistic effect of SARS-CoV-2 virus protein on...
Source: Biological Trace Element Research - August 22, 2023 Category: Biology Authors: Shatha A Albalawi Raneem A Albalawi Amaal A Albalawi Raghad F Alanazi Raghad M Almahlawi Basma S Alhwity Bashayer D Alatawi Nehal Elsherbiny Saleh F Alqifari Mohamed S Abdel-Maksoud Source Type: research
Estimating SARS-CoV-2 infections and associated changes in COVID-19 severity and fatality
CONCLUSIONS: Since 2021, changes in the dominant SARS-CoV-2 variant, vaccination rollout, and the shift of infection to younger ages have reduced SARS-CoV-2 infection ascertainment. The same factors, combined with the improvement of patient management and care, contributed to a massive reduction in the severity and fatality of COVID-19.PMID:37599801 | PMC:PMC10432583 | DOI:10.1111/irv.13181
Source: Respiratory Care - August 21, 2023 Category: Respiratory Medicine Authors: Valentina Marziano Giorgio Guzzetta Francesco Menegale Chiara Sacco Daniele Petrone Alberto Mateo Urdiales Martina Del Manso Antonino Bella Massimo Fabiani Maria Fenicia Vescio Flavia Riccardo Piero Poletti Mattia Manica Agnese Zardini Valeria d'Andrea Fi Source Type: research
TWiV 1034: Clinical update with Dr. Daniel Griffin
In his weekly clinical update, Dr. Griffin discusses the immunogenicity, safety, and preliminary efficacy evaluation of OVX836, a nucleoprotein-based universal influenza A vaccine candidate, association between nose picking and SARS-CoV-2 incidence, a cohort study in hospital health care workers; effect of COVID-19 vaccination and booster on maternal-fetal outcomes, dynamics of inflammatory responses after SARS-CoV-2 infection by vaccination status in the USA, does monoclonal antibody treatment for COVID-19 impact short and long- term outcomes in a large generalizable population, persistent endothelial dysfunction in post-...
Source: This Week in Virology - MP3 Edition - August 12, 2023 Category: Virology Authors: Vincent Racaniello Source Type: podcasts
An easy pill to swallow: oral recombinant vaccines for the 21st century
Curr Opin Immunol. 2023 Aug 8;84:102374. doi: 10.1016/j.coi.2023.102374. Online ahead of print.ABSTRACTOral vaccines have a distinctive advantage of stimulating immune responses in the mucosa, where numerous pathogens gain entry and cause disease. Although various efforts have been attempted to create recombinant mucosal vaccines that provoke strong immunogenicity, the outcomes in clinical trials have been weak or inconsistent. Therefore, next-generation mucosal vaccines are needed that are more immunogenic. Here, we discuss oral vaccines with an emphasis on a next-generation mucosal vaccine that utilizes a nonreplicating ...
Source: Current Opinion in Immunology - August 10, 2023 Category: Allergy & Immunology Authors: Molly R Braun Becca A Flitter William Sun Sean N Tucker Source Type: research
